Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Commvault Announces Pricing of Upsized Convertible Senior Notes Offering

(NASDAQ:CVLT) Opportunistic capital raise with proceeds used to enhance strategic flexibility A portion of the proceeds to be used to purchase capped calls to offset any share dilution up to a 100%...

How does this opportunistic capital raise alter Commvault's balance sheet strength and leverage ratios compared to industry peers? What are the specific terms and pricing of the capped calls being purchased, and how do they impact the overall cost of capital? How will the upsized convertible senior notes issuance affect dilution and the current share price of CVLT?
Symbol: CVLT
Finance
12 days ago
Read more prnewswire

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

(NASDAQ:BIOA) STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplement...

How does Leqembi's subcutaneous formulation under Fast Track compare to existing Alzheimer’s treatments and competitors in terms of market potential and revenue growth? What is the anticipated timeline for FDA review and potential approval, and how might that timeline impact the market's perception of BIOA's valuation? How will the rolling sBLA submission for subcutaneous Leqembi influence BioArctic's short‑term stock price and volatility?
Symbol: BIOA
Regulatory
12 days ago
Read more prnewswire

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

(NASDAQ:BIOA) STOCKHOLM, Sept. 2, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplement...

How does this subcutaneous formulation compare to competing early‑Alzheimer's therapies in terms of market share potential and pricing power? What impact will the Fast Track designation and potential approval have on BioArctic's (BIOA) revenue forecasts and share price in the short to medium term? How likely is the FDA to grant approval for the subcutaneous Leqembi® Iqlik™ formulation and what is the expected timeline for a decision?
Symbol: BIOA
Regulatory
12 days ago
Read more prnewswire

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

(NASDAQ:BIOT) Proposal No. 1 (The Acquisition Proposal) to be adjourned pending final NASDAQ approval; Company operations, financings and closing of the merger transaction remain not impacted Prop...

How might the adjournment of Proposal No. 1 affect short‑term market sentiment and liquidity for BIOT shares? What are the potential financial and dilution effects of the pending Acquisition Proposal on current shareholders? When is BioSig expected to receive final NASDAQ approval and could any delays impact the merger timeline?
Symbol: BIOT
Mergers
12 days ago
Read more globenewswire